Immune responses rely on the efficient movement of immune cells within the complex and geometrically unpredictable ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales ...

Restricted availability under an FDA-mandated drug safety program has limited the reach of CAR-T cell therapies for certain blood cancers—until now. | The FDA has removed the REMS requirements ...

T cells transformed in vivo to target B cells could widen the scope of diseases treated by chimeric antigen receptor T-cell therapy.

CAR T-cell therapy has the potential to revolutionise how we treat certain types of cancer by genetically engineering someone’s own immune cells to attack the disease – but it is also ...

Adding IL-12 to mRNA vaccines can lead to longer lasting protective effect and a potential approach for reducing the risk of cancer.

Read about a CAR T cell therapy that appears effective against light chain (AL) amyloidosis.

Juri Biosciences is offering EpimAb up to $210 million biobucks for licensing rights to a T-cell engager designed to treat metastatic prostate cancer.

Local immune effector cell–associated toxicity syndrome is a newly identified side effect observed in many patients receiving CD19-targeting CAR T-cell therapy for autoimmune conditions.

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments ...

A next-generation, anti-CD19 enhanced (or "armored") CAR T-cell product showed promising efficacy and safety in a phase I trial of lymphoma patients who had previously failed anti-CD19 CAR T-cell ...